Document is current

Article History

Received: 24 October 2024

Accepted: 8 October 2025

First Online: 4 December 2025

Declarations

:

: This OLE will be carried out in compliance with the protocol, the ethical principles laid down in the Declaration of Helsinki, in accordance with the International Council for Harmonization (ICH) Guidelines for Good Clinical Practice (GCP), the European Union (EU) directive 2001/20/European Commission/EU regulation 536/2014, the Japanese GCP regulations, and other relevant regulations.

: WW has received fees for advisory boards from Alentis Therapeutics, Boehringer Ingelheim, BMS, Sanofi, and Pliant; received fees as a paid consultant from Alentis Therapeutics, Boehringer Ingelheim, BMS, Sanofi, and Pliant; and has received funding from Alentis Therapeutics, Boehringer Ingelheim and Sanofi. All payments were paid to his institution. LR has received consultancy fees from Chiesi Farmaceutici, CSL Behring, Bristol Myers Squibb, Veracyte, DevPro, GlaxoSmithKline, Gilead, and Biogen; speaker fees from CSL Behring and Bristol Myers Squibb; and advisory fees for Roche, Avalyn Pharma, and Pliant Therapeutics. SA has received research grants from Boehringer Ingelheim and Janssen; and consultancy fees from Boehringer Ingelheim, Novartis, AbbVie, CSL Behring, and AstraZeneca. AA has received research grants and speaker fees from Boehringer Ingelheim and Taiho Pharm. Co.; and has been an advisory committee member for Boehringer Ingelheim, Taiho Pharm. Co., Toray Co. and Kyorin Pharm. Co. VC has received unrestricted grants from Boehringer Ingelheim; consulting fees from AstraZeneca, Boehringer Ingelheim, Celgene/BMS, CSL Behring, Ferrer, Galapagos, Pliant Therapeutics, PureTech, RedX, Roche, Sanofi, and Shionogi; lecture fees from Boehringer Ingelheim and Roche; support for attending meetings from Boehringer Ingelheim and Roche; has participated in data and safety monitoring boards for Galapagos, Galecto, and Roche; and has been on an adjudication committee for FibroGen. AMHV has received speaker fees from Boehringer Ingelheim, Janssen, Medscape, Merck Sharp & Dohme, Novartis, and Roche; consultancy fees from AbbVie, ARXX, Boehringer Ingelheim, Genentech, Jannsen, Medscape, Merck Sharp & Dohme, Pliant Therapeutics, Roche, and Werfen; and grant/research support from Boehringer Ingelheim and Janssen. MK is an advisor or review panel member for Boehringer Ingelheim, Galapagos, and Roche; and has received consultancy fees, grants, and speaker fees from Boehringer Ingelheim and Roche. JMO has received consultancy fees and grants from Boehringer Ingelheim; and consultancy fees from Roche/Genentech and Lupin Pharmaceuticals. FJM has served on a steering committee, advisory board, data safety monitoring board, or adjudication committee for Afferent/Merck, Bayer, Biogen, Boehringer Ingelheim, DevPro, Nitto, Novartis, Respivant, Roche, and Veracyte; and has received consulting fees or payment for presentations from AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Bridge Biotherapeutics, CSL Behring, DevPro, IQVIA, Lung Therapeutics, Roche/Genentech, Sanofi, Shionogi, twoXAR, United Therapeutics, and Veracyte. CV has received personal fees from Boehringer Ingelheim, Roche, and Bristol Myers Squibb; and support for attending meetings from Boehringer Ingelheim and Roche. MSW has received grants from AstraZeneca-Daiichi, Boehringer Ingelheim, Roche, The Netherlands Organisation for Health Research and Development, The Dutch Lung Foundation, and The Dutch Pulmonary Society; consulting fees from Boehringer Ingelheim, Galapagos, Bristol Myers Squibb, Galecto, Respivant, NeRRe Therapeutics, Horizon Therapeutics, PureTech Health, Kinevant Sciences, Molecure, CSL Behring, Thyron, and Vicore; speaker fees from Boehringer Ingelheim, Galapagos, Roche, Novartis, and CSL Behring; support for attending meetings from Boehringer Ingelheim, Galapagos, and Roche; has participated in advisory boards for Savara, Galapagos, and Dutch lung fibrosis and sarcoidosis patient associations (unpaid). All grants and fees were paid to her institution. AJ is a paid consultant for Elderbrook Solutions GmbH, contracted by Boehringer Ingelheim, and a paid consultant for AbbVie. MK, CC, CD, and GW are employees of Boehringer Ingelheim. TMM has received speaker fees from Boehringer Ingelheim and Roche/Genentech; and worked as a paid consultant for Boehringer Ingelheim, Roche/Genentech, AstraZeneca, Bayer, Blade Therapeutics, Bristol Myers Squibb, Galapagos, Galecto, GlaxoSmithKline, IQVIA, Pliant Therapeutics, Respivant, Theravance, and Veracyte.